- Home
- TYRA vs SVRA Comparison
TYRA vs SVRA Comparison
Compare TYRA & SVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TYRA
- SVRA
- Stock Information
- Founded
- TYRA 2018
- SVRA 2007
- Country
- TYRA United States
- SVRA United States
- Employees
- TYRA N/A
- SVRA N/A
- Industry
- TYRA Biotechnology: Pharmaceutical Preparations
- SVRA Biotechnology: Pharmaceutical Preparations
- Sector
- TYRA Health Care
- SVRA Health Care
- Exchange
- TYRA Nasdaq
- SVRA Nasdaq
- Market Cap
- TYRA 576.6M
- SVRA 528.3M
- IPO Year
- TYRA 2021
- SVRA N/A
- Fundamental
- Price
- TYRA $9.23
- SVRA $2.06
- Analyst Decision
- TYRA Strong Buy
- SVRA Buy
- Analyst Count
- TYRA 7
- SVRA 7
- Target Price
- TYRA $30.86
- SVRA $7.57
- AVG Volume (30 Days)
- TYRA 360.4K
- SVRA 2.5M
- Earning Date
- TYRA 08-06-2025
- SVRA 08-11-2025
- Dividend Yield
- TYRA N/A
- SVRA N/A
- EPS Growth
- TYRA N/A
- SVRA N/A
- EPS
- TYRA N/A
- SVRA N/A
- Revenue
- TYRA N/A
- SVRA N/A
- Revenue This Year
- TYRA N/A
- SVRA N/A
- Revenue Next Year
- TYRA N/A
- SVRA N/A
- P/E Ratio
- TYRA N/A
- SVRA N/A
- Revenue Growth
- TYRA N/A
- SVRA N/A
- 52 Week Low
- TYRA $6.42
- SVRA $1.89
- 52 Week High
- TYRA $29.60
- SVRA $5.11
- Technical
- Relative Strength Index (RSI)
- TYRA 41.84
- SVRA 34.43
- Support Level
- TYRA $10.11
- SVRA $2.13
- Resistance Level
- TYRA $10.68
- SVRA $2.49
- Average True Range (ATR)
- TYRA 0.79
- SVRA 0.15
- MACD
- TYRA -0.08
- SVRA -0.01
- Stochastic Oscillator
- TYRA 7.05
- SVRA 8.41
About TYRA Tyra Biosciences Inc.
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are TYRA-300, TYRA-200, and TYRA-430: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.
About SVRA Savara Inc.
Savara Inc is a biopharmaceutical company. It is focused on rare respiratory diseases. The company's program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). It has one segment specialty pharmaceuticals within the respiratory system.